Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) vs 10X Genomics Inc (TXG) Price & Performance

Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETFTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF vs 10X Genomics Inc — how do they compare? Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.6, while 10X Genomics Inc trades at $67.8 (market cap $8.55B). Which is the better fit depends on your goals.

PDBCTXG
52-Week High
$19.60$67.29
52-Week Low
$13.16$11.34
Market Cap
$8.55B
Sector
Health
Enterprise Value
$8.08B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF

PDBC, the Invesco Optimum Yield Diversified Commodity Strategy ETF, trades at $19.30, up 1.53% with a bullish technical signal from moving averages. Recent institutional buying from Concurrent Investment Advisors and Geneos Wealth Management signals confidence, though oscillators show bearish momentum with RSI levels indicating potential overbought conditions. The fund has delivered strong returns, outperforming the S&P 500 by nearly 10 percentage points since March 2024.

Commodity momentum faces headwinds despite geopolitical tensions, with a Seeking Alpha downgrade to hold citing weakening technicals. The fund offers defensive exposure amid market shifts away from tech, but investors face risks from potential commodity price volatility and Middle East conflict impacts on oil markets.

10X Genomics Inc

TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.

The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF

The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.

Read more on PDBC

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG